Adlyxin Purple Book BLA 208471

BLA number
208471
Proprietary names
Adlyxin
Proper names
lixisenatide
Applicant
Sanofi-Aventis U.S. LLC
Center
CDER
First observed release
2020-05-01
Latest observed release
2026-06-01
Newest archive release
2026-06-01
FDA patent list
No patents listed in the captured FDA patent list; source updated 2025-06-11
Coverage
Present in newest release

Latest Known Product Presentations#

Product, Proprietary name, Proper name table
ProductProprietary nameProper nameLicense typeStrengthDosage formRoutePresentationMarketingLicensureApprovalPatent list provided
001Adlyxinlixisenatide351(a)150MCG/3ML (50MCG/ML)InjectionSubcutaneousAutoinjectorDiscVoluntarily Revoked2016-07-27
002Adlyxinlixisenatide351(a)300MCG/3ML (100MCG/ML)InjectionSubcutaneousAutoinjectorDiscVoluntarily Revoked2016-07-27

Published Patent List#

No patents for this BLA were listed in the FDA Purple Book patent list captured from the source updated 2025-06-11.

Official Monthly Change Events#

Release, Event, Product table
ReleaseEventProductNameLicense typeStatusApplicant
2026-04-01U001Adlyxin351(a)DiscSanofi-Aventis U.S. LLC
2026-04-01U002Adlyxin351(a)DiscSanofi-Aventis U.S. LLC
2023-07-01U001Adlyxin351(a)DiscSanofi-Aventis U.S. LLC
2023-07-01U002Adlyxin351(a)DiscSanofi-Aventis U.S. LLC
2021-08-01U002Adlyxin351(a)RxSanofi-Aventis U.S. LLC
2021-05-01U001Adlyxin351(a)RxSanofi-Aventis U.S. LLC
2021-05-01U002Adlyxin351(a)RxSanofi-Aventis U.S. LLC
2020-05-01R001Adlyxin351(a)RxSanofi-Aventis US LLC
2020-05-01R002Adlyxin351(a)RxSanofi-Aventis US LLC

Observed Product State History#

Release, Product, Name table
ReleaseProductNameLicense typeMarketingLicensureApproval
2026-04-01001Adlyxin351(a)DiscVoluntarily Revoked2016-07-27
2026-04-01002Adlyxin351(a)DiscVoluntarily Revoked2016-07-27
2023-07-01001Adlyxin351(a)DiscLicensed2016-07-27
2023-07-01002Adlyxin351(a)DiscLicensed2016-07-27
2020-05-01001Adlyxin351(a)RxLicensed2016-07-27
2020-05-01002Adlyxin351(a)RxLicensed2016-07-27